Development and construct validation of the angioedema quality of life questionnaire

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 10, 2012, Pages 1289-1298

  Weller, K ^a   Groffik, A ^b   Magerl, M ^a   Tohme, N ^a   Martus, P ^c   Krause, K ^a   Metz, M ^a   Staubach, P ^b   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

angioedema; hereditary; quality of life; urticaria; validation

Indexed keywords

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; CONTENT VALIDITY; CRONBACH ALPHA COEFFICIENT; DISEASE ACTIVITY; FACTORIAL ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; SCORING SYSTEM; STRUCTURE ANALYSIS; TEST RETEST RELIABILITY; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84866446232     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12007     Document Type: Article

References (31)

1. Banerji A, Sheffer AL,. The spectrum of chronic angioedema. Allergy Asthma Proc 2009; 30: 11-16.
2. Kaplan AP, Greaves MW,. Angioedema. J Am Acad Dermatol 2005; 53: 373-388. (Pubitemid 41195957)
3. Maurer M, Magerl M,. Hereditary angioedema: an update on available therapeutic options. J Dtsch Dermatol Ges 2010; 8: 663-672.
4. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011; 66: 317-330.
5. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
6. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT,. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-414.
7. Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010; 65: 290-295.
8. Juniper EF, Guyatt GH, Streiner DL, King DR,. Clinical impact versus factor analysis for quality of life questionnaire construction. J Clin Epidemiol 1997; 50: 233-238. (Pubitemid 27165699)
9. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60: 1073-1078. (Pubitemid 40942764)
10. Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009; 64: 927-936.
11. Kocaturk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, et al. Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. Acta Derm Venereol 2012; 92: 419-425.
12. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY,. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
13. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
14. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl 2): 17-22.
15. Budzynski J, Pulkowski G, Suppan K, Fabisiak J, Majer M, Klopocka M, et al. Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey. Health Qual Life Outcomes 2011; 9: 77.
16. Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hormann K, et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 2004; 113: 663-668. (Pubitemid 38530420)
17. Yarlas AS, White MK, Yang M, Saris-Baglama RN, Bech PG, Christensen T,. Measuring the health status burden in hemodialysis patients using the SF-36(R) health survey. Qual Life Res 2011; 20: 383-389.
18. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
19. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
20. European Medicines Agency (EMA), COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP). Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003637.pdf. Last accessed June 2012.
21. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
22. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
23. Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-1611.
24. Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M,. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012. doi: 10.1111/j.1398-9995.2012.02853.x. [Epub ahead of print].
25. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827 e814.
26. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
27. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
28. Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS,. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2012; 108: 20-24.
29. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M,. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777-780. (Pubitemid 351591864)
30. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health 2011; 14: 978-988.
31. Floyd F, WIdaman K,. Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess 1995; 7: 286-299.